211 related articles for article (PubMed ID: 24030748)
1. Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors.
Chan AK; Pang JC; Chung NY; Li KK; Poon WS; Chan DT; Shi Z; Chen L; Zhou L; Ng HK
Mod Pathol; 2014 Mar; 27(3):332-42. PubMed ID: 24030748
[TBL] [Abstract][Full Text] [Related]
2. [Diagnostic and prognostic roles of loss of CIC protein expression in oligodendroglial tumors].
Liu CC; Zhang LY; Wang LM; Wang DD; Fu YJ; Cai YN; Lu DH; Piao YS
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):679-683. PubMed ID: 29050068
[No Abstract] [Full Text] [Related]
3. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas.
Sahm F; Koelsche C; Meyer J; Pusch S; Lindenberg K; Mueller W; Herold-Mende C; von Deimling A; Hartmann C
Acta Neuropathol; 2012 Jun; 123(6):853-60. PubMed ID: 22588899
[TBL] [Abstract][Full Text] [Related]
4. ETV/Pea3 family transcription factor-encoding genes are overexpressed in CIC-mutant oligodendrogliomas.
Padul V; Epari S; Moiyadi A; Shetty P; Shirsat NV
Genes Chromosomes Cancer; 2015 Dec; 54(12):725-33. PubMed ID: 26357005
[TBL] [Abstract][Full Text] [Related]
5. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers.
Yip S; Butterfield YS; Morozova O; Chittaranjan S; Blough MD; An J; Birol I; Chesnelong C; Chiu R; Chuah E; Corbett R; Docking R; Firme M; Hirst M; Jackman S; Karsan A; Li H; Louis DN; Maslova A; Moore R; Moradian A; Mungall KL; Perizzolo M; Qian J; Roldan G; Smith EE; Tamura-Wells J; Thiessen N; Varhol R; Weiss S; Wu W; Young S; Zhao Y; Mungall AJ; Jones SJ; Morin GB; Chan JA; Cairncross JG; Marra MA
J Pathol; 2012 Jan; 226(1):7-16. PubMed ID: 22072542
[TBL] [Abstract][Full Text] [Related]
6. Alpha-internexin and altered CIC expression as a supportive diagnostic marker for oligodendroglial tumors with the 1p/19q co-deletion.
Nagaishi M; Suzuki A; Nobusawa S; Yokoo H; Nakazato Y
Brain Tumor Pathol; 2014 Oct; 31(4):257-64. PubMed ID: 24197863
[TBL] [Abstract][Full Text] [Related]
7. Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.
Cahill DP; Louis DN; Cairncross JG
CNS Oncol; 2015; 4(5):287-94. PubMed ID: 26545048
[TBL] [Abstract][Full Text] [Related]
8. Novel CIC point mutations and an exon-spanning, homozygous deletion identified in oligodendroglial tumors by a comprehensive genomic approach including transcriptome sequencing.
Eisenreich S; Abou-El-Ardat K; Szafranski K; Campos Valenzuela JA; Rump A; Nigro JM; Bjerkvig R; Gerlach EM; Hackmann K; Schröck E; Krex D; Kaderali L; Schackert G; Platzer M; Klink B
PLoS One; 2013; 8(9):e76623. PubMed ID: 24086756
[TBL] [Abstract][Full Text] [Related]
9. Mutations in CIC and FUBP1 contribute to human oligodendroglioma.
Bettegowda C; Agrawal N; Jiao Y; Sausen M; Wood LD; Hruban RH; Rodriguez FJ; Cahill DP; McLendon R; Riggins G; Velculescu VE; Oba-Shinjo SM; Marie SK; Vogelstein B; Bigner D; Yan H; Papadopoulos N; Kinzler KW
Science; 2011 Sep; 333(6048):1453-5. PubMed ID: 21817013
[TBL] [Abstract][Full Text] [Related]
10. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.
Li YX; Shi Z; Aibaidula A; Chen H; Tang Q; Li KK; Chung NY; Chan DT; Poon WS; Mao Y; Wu J; Zhou L; Chan AK; Ng HK
Oncotarget; 2016 Oct; 7(40):64615-64630. PubMed ID: 27556304
[TBL] [Abstract][Full Text] [Related]
11. Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.
Frenel JS; Leux C; Loussouarn D; Le Loupp AG; Leclair F; Aumont M; Mervoyer A; Martin S; Denis MG; Campone M
J Neurooncol; 2013 Aug; 114(1):85-91. PubMed ID: 23681562
[TBL] [Abstract][Full Text] [Related]
12. Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization.
Jeon YK; Park K; Park CK; Paek SH; Jung HW; Park SH
Neuropathology; 2007 Feb; 27(1):10-20. PubMed ID: 17319279
[TBL] [Abstract][Full Text] [Related]
13. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology.
Ammendola S; Caldonazzi N; Simbolo M; Piredda ML; Brunelli M; Poliani PL; Pinna G; Sala F; Ghimenton C; Scarpa A; Barresi V
Virchows Arch; 2021 Nov; 479(5):987-996. PubMed ID: 34165590
[TBL] [Abstract][Full Text] [Related]
14. Oligodendrogliomas: new insights from the genetics and perspectives.
Alentorn A; Sanson M; Idbaih A
Curr Opin Oncol; 2012 Nov; 24(6):687-93. PubMed ID: 22913971
[TBL] [Abstract][Full Text] [Related]
15. Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity.
Baumgarten P; Harter PN; Tönjes M; Capper D; Blank AE; Sahm F; von Deimling A; Kolluru V; Schwamb B; Rabenhorst U; Starzetz T; Kögel D; Rieker RJ; Plate KH; Ohgaki H; Radlwimmer B; Zörnig M; Mittelbronn M
Neuropathol Appl Neurobiol; 2014 Feb; 40(2):205-16. PubMed ID: 24117486
[TBL] [Abstract][Full Text] [Related]
16. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.
Kouwenhoven MC; Gorlia T; Kros JM; Ibdaih A; Brandes AA; Bromberg JE; Mokhtari K; van Duinen SG; Teepen JL; Wesseling P; Vandenbos F; Grisold W; Sipos L; Mirimanoff R; Vecht CJ; Allgeier A; Lacombe D; van den Bent MJ
Neuro Oncol; 2009 Dec; 11(6):737-46. PubMed ID: 19224764
[TBL] [Abstract][Full Text] [Related]
18. Alpha internexin expression related with molecular characteristics in adult glioblastoma and oligodendroglioma.
Suh JH; Park CK; Park SH
J Korean Med Sci; 2013 Apr; 28(4):593-601. PubMed ID: 23579442
[TBL] [Abstract][Full Text] [Related]
19. Prognosis of oligodendroglial tumor with ring enhancement showing central necrotic portion.
Choi KY; Jung TY; Jung S; Kim YH; Moon KS; Kim IY; Kang SS; Lee KH
J Neurooncol; 2011 May; 103(1):103-10. PubMed ID: 20737192
[TBL] [Abstract][Full Text] [Related]
20. Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors.
Chen H; Thomas C; Munoz FA; Alexandrescu S; Horbinski CM; Olar A; McGuone D; Camelo-Piragua S; Wang L; Pentsova E; Phillips J; Aldape K; Chen W; Iafrate AJ; Chi AS; Zagzag D; Golfinos JG; Placantonakis DG; Rosenblum M; Ohman-Strickland P; Hameed M; Snuderl M
Neuro Oncol; 2019 Sep; 21(9):1164-1174. PubMed ID: 31140557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]